Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Jun;65(6):2107–2111. doi: 10.1128/iai.65.6.2107-2111.1997

Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers.

D A Sack 1, J Shimko 1, R B Sack 1, J G Gomes 1, K MacLeod 1, D O'Sullivan 1, D Spriggs 1
PMCID: PMC175291  PMID: 9169739

Abstract

During development of Peru-15, a new live oral vaccine for cholera, the role of buffer needed to be evaluated. Generally, oral bacterial vaccines are acid labile and need to be administered by using a formulation which protects them from gastric acid. We compared three different buffers for use with Peru-15, including a standard bicarbonate-ascorbic acid buffer, Alka-Seltzer, and a new electrolyte-rice buffer, CeraVacx. Saline served as the control. Thirty-nine healthy adult volunteers received Peru-15 (10(8) CFU) with one of the three buffers or saline in a double-masked study. The volunteers were monitored for symptoms for 7 days after the dose, serum was tested for antibody responses by vibriocidal antibody and immunoglobulin G antitoxin enzyme-linked immunosorbent assays, and stool samples were tested for excretion of the vaccine strain. Side effects were minimal in all groups. All 30 volunteers who took Peru-15 with a buffer showed significant rises in vibriocidal antibody titer. The magnitude of the rises was higher in the CeraVacx group than in the other two buffer groups. Four of nine volunteers who took the vaccine with saline also showed increased titers, but they were lower than those in any of the three buffer groups. Excretion of the vaccine strain was similar in the buffer groups, but excretion was not associated with the magnitude of the vibriocidal responses. Excretion of Peru-15 was not detected in the saline group. We conclude that buffer does amplify the serological response to Peru-15 and that CeraVacx may provide benefits not provided by other buffers.

Full Text

The Full Text of this article is available as a PDF (131.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed Z. U., Sarker M. R., Sack D. A. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y. Vaccine. 1990 Apr;8(2):153–158. doi: 10.1016/0264-410x(90)90139-d. [DOI] [PubMed] [Google Scholar]
  2. Baqar S., Applebee L. A., Bourgeois A. L. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infect Immun. 1995 Sep;63(9):3731–3735. doi: 10.1128/iai.63.9.3731-3735.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baqar S., Bourgeois A. L., Schultheiss P. J., Walker R. I., Rollins D. M., Haberberger R. L., Pavlovskis O. R. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine. 1995 Jan;13(1):22–28. doi: 10.1016/0264-410x(95)80006-y. [DOI] [PubMed] [Google Scholar]
  4. Bromander A. K., Kjerrulf M., Holmgren J., Lycke N. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand J Immunol. 1993 Apr;37(4):452–458. doi: 10.1111/j.1365-3083.1993.tb03318.x. [DOI] [PubMed] [Google Scholar]
  5. Christy C., Madore H. P., Pichichero M. E., Gala C., Pincus P., Vosefski D., Hoshino Y., Kapikian A., Dolin R. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J. 1988 Sep;7(9):645–650. doi: 10.1097/00006454-198809000-00009. [DOI] [PubMed] [Google Scholar]
  6. Clemens J. D., Jertborn M., Sack D., Stanton B., Holmgren J., Khan M. R., Huda S. Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine. J Infect Dis. 1986 Jul;154(1):175–178. doi: 10.1093/infdis/154.1.175. [DOI] [PubMed] [Google Scholar]
  7. Clemens J. D., Sack D. A., Harris J. R., Chakraborty J., Khan M. R., Stanton B. F., Kay B. A., Khan M. U., Yunus M., Atkinson W. Field trial of oral cholera vaccines in Bangladesh. Lancet. 1986 Jul 19;2(8499):124–127. doi: 10.1016/s0140-6736(86)91944-6. [DOI] [PubMed] [Google Scholar]
  8. Concha A., Giraldo A., Castañeda E., Martínez M., de la Hoz F., Rivas F., Depetris A., Svennerholm A. M., Sack D. A. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Bull Pan Am Health Organ. 1995 Dec;29(4):312–321. [PubMed] [Google Scholar]
  9. Cryz S. J., Jr, Levine M. M., Kaper J. B., Fürer E., Althaus B. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine. 1990 Dec;8(6):577–580. doi: 10.1016/0264-410x(90)90012-b. [DOI] [PubMed] [Google Scholar]
  10. Dickinson B. L., Clements J. D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun. 1995 May;63(5):1617–1623. doi: 10.1128/iai.63.5.1617-1623.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ferreccio C., Levine M. M., Rodriguez H., Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis. 1989 Apr;159(4):766–769. doi: 10.1093/infdis/159.4.766. [DOI] [PubMed] [Google Scholar]
  12. Hohmann E. L., Oletta C. A., Killeen K. P., Miller S. I. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis. 1996 Jun;173(6):1408–1414. doi: 10.1093/infdis/173.6.1408. [DOI] [PubMed] [Google Scholar]
  13. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 1993 Sep;11(12):1179–1184. doi: 10.1016/0264-410x(93)90039-z. [DOI] [PubMed] [Google Scholar]
  14. Kenner J. R., Coster T. S., Taylor D. N., Trofa A. F., Barrera-Oro M., Hyman T., Adams J. M., Beattie D. T., Killeen K. P., Spriggs D. R. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis. 1995 Oct;172(4):1126–1129. doi: 10.1093/infdis/172.4.1126. [DOI] [PubMed] [Google Scholar]
  15. Kotloff K. L., Losonsky G. A., Nataro J. P., Wasserman S. S., Hale T. L., Taylor D. N., Newland J. W., Sadoff J. C., Formal S. B., Levine M. M. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine. 1995 Apr;13(5):495–502. doi: 10.1016/0264-410x(94)00011-b. [DOI] [PubMed] [Google Scholar]
  16. Kärnell A., Sweiha H., Lindberg A. A. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes. Vaccine. 1992;10(3):167–174. doi: 10.1016/0264-410x(92)90007-7. [DOI] [PubMed] [Google Scholar]
  17. Lebens M., Holmgren J. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier. Dev Biol Stand. 1994;82:215–227. [PubMed] [Google Scholar]
  18. Levine M. M., Kaper J. B., Herrington D., Ketley J., Losonsky G., Tacket C. O., Tall B., Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–470. doi: 10.1016/s0140-6736(88)90120-1. [DOI] [PubMed] [Google Scholar]
  19. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol. 1992 Sep;22(9):2277–2281. doi: 10.1002/eji.1830220915. [DOI] [PubMed] [Google Scholar]
  20. Lång H., Jonson G., Holmgren J., Palva E. T. The maltose regulon of Vibrio cholerae affects production and secretion of virulence factors. Infect Immun. 1994 Nov;62(11):4781–4788. doi: 10.1128/iai.62.11.4781-4788.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nalin D. R., Levine M. M., Rhead J., Bergquist E., Rennels M., Hughes T., O'Donnel S., Hornick R. B. Cannabis, hypochlorhydria, and cholera. Lancet. 1978 Oct 21;2(8095):859–862. doi: 10.1016/s0140-6736(78)91569-6. [DOI] [PubMed] [Google Scholar]
  22. Nalin D. R., Levine R. J., Levine M. M., Hoover D., Bergquist E., McLaughlin J., Libonati J., Alam J., Hornick R. B. Cholera, non-vibrio cholera, and stomach acid. Lancet. 1978 Oct 21;2(8095):856–859. doi: 10.1016/s0140-6736(78)91568-4. [DOI] [PubMed] [Google Scholar]
  23. Rollwagen F. M., Pacheco N. D., Clements J. D., Pavlovskis O., Rollins D. M., Walker R. I. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine. 1993 Oct;11(13):1316–1320. doi: 10.1016/0264-410x(93)90101-3. [DOI] [PubMed] [Google Scholar]
  24. Sack D. A., Clemens J. D., Huda S., Harris J. R., Khan M. R., Chakraborty J., Yunus M., Gomes J., Siddique O., Ahmed F. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis. 1991 Aug;164(2):407–411. doi: 10.1093/infdis/164.2.407. [DOI] [PubMed] [Google Scholar]
  25. Sack D. A. Use of oral rehydration therapy in acute watery diarrhoea. A practical guide. Drugs. 1991 Apr;41(4):566–573. doi: 10.2165/00003495-199141040-00005. [DOI] [PubMed] [Google Scholar]
  26. Sanchez J. L., Trofa A. F., Taylor D. N., Kuschner R. A., DeFraites R. F., Craig S. C., Rao M. R., Clemens J. D., Svennerholm A. M., Sadoff J. C. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J Infect Dis. 1993 Jun;167(6):1446–1449. doi: 10.1093/infdis/167.6.1446. [DOI] [PubMed] [Google Scholar]
  27. Sanchez J. L., Vasquez B., Begue R. E., Meza R., Castellares G., Cabezas C., Watts D. M., Svennerholm A. M., Sadoff J. C., Taylor D. N. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet. 1994 Nov 5;344(8932):1273–1276. doi: 10.1016/s0140-6736(94)90755-2. [DOI] [PubMed] [Google Scholar]
  28. Simanjuntak C. H., Paleologo F. P., Punjabi N. H., Darmowigoto R., Soeprawoto, Totosudirjo H., Haryanto P., Suprijanto E., Witham N. D., Hoffman S. L. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet. 1991 Oct 26;338(8774):1055–1059. doi: 10.1016/0140-6736(91)91910-m. [DOI] [PubMed] [Google Scholar]
  29. Svennerholm A. M., Holmgren J., Sack D. A. Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea. Vaccine. 1989 Jun;7(3):196–198. doi: 10.1016/0264-410x(89)90228-4. [DOI] [PubMed] [Google Scholar]
  30. Tauchi Y., Yamada A., Kawakita T., Saito Y., Suzuki A., Yoshikai Y., Nomoto K. Enhancement of immunoglobulin A production in Peyer's patches by oral administration of a traditional Chinese medicine, xiao-chai-hu-tang (Shosaiko-to). Immunopharmacol Immunotoxicol. 1993 Mar-Jun;15(2-3):251–272. doi: 10.3109/08923979309025998. [DOI] [PubMed] [Google Scholar]
  31. Vajdy M., Lycke N. Stimulation of antigen-specific T- and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology. 1993 Oct;80(2):197–203. [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES